Published in final edited form as:

J Am Chem Soc. 2009 November 25; 131(46): 16669–16671. doi:10.1021/ja907136d.

Total Synthesis of the 2,6-Sialylated Immunoglobulin G Glycopeptide Fragment in Homogeneous Form

Ping Wang[†], Jianglong Zhu[†], Yu Yuan[†], and Samuel J. Danishefsky^{*,†,‡}

[†]Laboratory for Bioorganic Chemistry, Sloan-Kettering Institute for Cancer Research, 1275 York Avenue, New York, NY 10065

[‡]Department of Chemistry, Columbia University, Havemeyer Hall, 3000 Broadway, New York, NY 10027

Carbohydrate domains mediate the stability, folding, and biological activity of glycoproteins.

¹ Quality investigations into the impact of specific glycosylation patterns are complicated by formation of horrific mixtures of difficultly separable glycoforms. A major program underway in our laboratory seeks to address the challenge of obtaining single glycoforms of biologics through the *de novo* chemical synthesis of homogeneous glycopeptides and glycoproteins of established therapeutic value.²

Accordingly, we became interested in monomeric immunoglobulin G (IgG) purified from intravenous immunoglobulin (IVIG). This therapeutically valuable anti-inflammatory agent is commonly employed in the treatment of autoimmune disorders, such as rheumatoid arthritis and immune thrombocytopenia. The biological activity of IVIG derives from its Fc fragment, which presents a biantennary tridecasaccharide, attached through an N-linkage to the Asn²⁹⁷ residue. Recently, Ravetch and coworkers discovered the critical role of the terminal 2,6-linked sialic acids of the glycan in mediating the anti-inflammatory activity of IVIG.³ Although the IVIG glycan is biosynthesized as a heterogeneous mixture, containing both 2,3- and 2,6-sialylated carbohydrate domains, only the Fc fragment possessing the 2,6-sialylated glycoform demonstrates appreciable anti-inflammatory activity in arthritic mice. Moreover, an IVIG Fc fragment possessing exclusively 2,6-sialic acid linkages was shown to be 10-fold more active in suppressing inflammation in mice than was an Fc fragment isolated from IVIG (containing both 2,6- and 2,3- linkages). These results suggest that an Fc peptide fragment presenting a homogeneous 2,6-sialylated glycan domain (cf. **1**) could be more potent and effective than the heterogeneous mixture currently employed in clinical settings.

We describe herein the chemical synthesis of homogeneous tridecasaccharide, **1**, possessing terminal 2,6-sialic acid linkages. We further describe the aspartylation of **1** with a peptide domain, thereby demonstrating the ability to convert it into a polyglycopolypeptide (see **28**). Accordingly, glycopeptidic constructs corresponding to the carbohydrate domain of immunoglobulin G can now be synthesized and screened.

The power of prioritized strategic bond disconnection as a means of guiding synthetic analysis, formalized by the Corey school,⁴ is well appreciated by students of chemical synthesis of complex target systems. Less well appreciated is a type of pattern recognition analysis which can be very helpful in devising total synthesis programs directed toward biologic level

*s-danishefsky@ski.mskcc.org.

Supporting Information Available: Experimental procedures, copies of spectral data, and characterization (PDF). This material is available free of charge *via* the Internet at <http://pubs.acs.org>

oligosaccharides.⁵ System **1** constitutes a significant challenge to chemical synthesis. Thus, the 13-mer contains an often troublesome (L)- α fucosyl ring (ring 5) branching from the “reducing end” GlcNAc of the terminal chitobiose (rings 1 and 2). It also presents the complex β -mannose linkage joining a β -mannose (ring 3) to the chitobiose core system. The β -mannoside (ring 3), in turn, is linked in a biantennary fashion from its C₃ and C₆ hydroxyls to two α -linked mannosides (see rings 6 and 7). The C₂ hydroxyls of these mannosides are linked in a β -fashion to two lactosamines, joined in 2,6 linkages to sialic acids (see rings 8-13). The β -linked mannose (ring 3) is also joined at its equatorial C₄ oxygen, in a β -linkage to a GlcNAc residue (see ring 4).

Based on earlier literature in this general area,⁶ it seemed likely that the most demanding phase of the synthesis would involve the attachment of the two trisaccharide ensembles – rings 8, 9, and 10 as well as rings 11, 12, and 13 – to their respective axial hydroxyl acceptor sites in ring 6 and ring 7. Looming particularly difficult was the prospect of introducing additional appendages at the interior C₂ axial hydroxyl of ring 7. Indeed, it was our hope for conciseness to conduct simultaneous azaglycosylations at both of these two acceptor sites to introduce β -glucosamine donor residues (see rings 8 and 11). These rings would in turn be joined at their C₄ equatorial hydroxyl groups, via β -linkages, to C₆ sialylated galactosyl donors. Ring 7 emanates from the particularly hindered C₃ hydroxyl site of ring 3 nestled between the glucosamine moiety at C₄, the axial hydroxyl at C₂, and the complex core (rings 1 and 2) substructure. In fact, previous attempts to use the more exposed C₆ hydroxyl of ring 3 as a viable acceptor site met with only the slightest of success. No glycosylation at all had been achieved at the much more hindered secondary hydroxyl acceptor site at C₃ of ring 3. Indeed, the key breakthrough involved the use of a phenylsulfamido function on the future ring 4 (see asterisk, compound **4**) to allow for introduction of rings 5, 6, and 7 (vide infra).

In Scheme 1, we recapitulate, by focusing on key building blocks, the strategic analysis, which eventually achieved success. Thus, as shown, we envisioned reaching tetrasaccharide **4** through coupling of trisaccharide **5** with sulfonamide donor **6**.⁷ As noted, the presence of the sulfonamide functionality on diol **4** would prove key to the efficient installation of the “wing” mannose and fucose units, furnishing core heptasaccharide **3**.⁸ Elongation of the mannose units with a β -GlcNAc donor would yield the nonasaccharide, **2**, which would finally be subjected to diglycosylation with disaccharide **10**, to afford the target compound, **1**. Happily, in this synthetic analysis, we were able to revisit the chemistry developed in connection with our longstanding glycal assembly program.⁹

Our synthesis of key intermediate **2** commenced with the known monosaccharides **11**¹⁰ and **12** (Scheme 2). Glycosylation of **12** with donor **11**, through exposure to NIS/TMSOTf¹¹ under sonication conditions, proceeded rapidly to afford the disaccharide in 82% yield.¹² Subsequent saponification furnished acceptor **13**. The latter was then glycosylated with donor **14**.¹³ to give trisaccharide **15** with good selectivity ($\beta/\alpha = 7:1$). The β -isomer was isolated in 65% yield. Following removal of the benzylidene acetal¹⁴ and selective benzylation of the resulting 4,6-diol, compound **5** was in hand. MeOTf-promoted¹⁵ glycosylation with glucosamine building block **6** afforded a 92% yield of **16** ($\beta/\alpha = 2.7:1$).

Sequential removal of the benzoate and PMB protecting groups of tetrasaccharide **16** afforded the 3,6-diol, **4**, in 77% yield over two steps. Two-fold glycosylation of **4** was accomplished with an excess of donor **7** and NIS/TMSOTf, to provide hexasaccharide **17** in 90% yield. The TBDPS group was cleaved upon exposure to HF/Py (88% yield). To the resultant free hydroxyl group was appended fluoride donor **8**,¹⁶ under Cp₂Zr(OTf)₂ mediation,¹⁷ to afford compound **19** in 93% yield and excellent selectivity ($\alpha/\beta = 12:1$). Following removal of the levulinoyl protecting group, intermediate **3** was in hand. BF₃·OEt₂-promoted diglycosylation of **3** was

achieved through the use of excess donor **9**.¹⁸ Finally, removal of the chloroacetate groups on the glucosamine units provided the target nonasaccharide **2** in 52% yield over two steps.

Having completed the synthesis of compound **2**, we now turned to the assembly of the disaccharide donor, **10** (Scheme 3). In the event, coupling of phosphite **21**¹⁹ and galactal **22**²⁰ proceeded smoothly to afford disaccharide **23** with good selectivity ($\alpha/\beta = 11:1$). The predominant α isomer was isolated in 74% yield. Oxidation of **23** with $\text{PhI}(\text{OAc})_2$ ²¹ followed by acetylation furnished disaccharide **24** in one pot.²² Finally, deprotection of the anomeric acetate was accomplished through exposure to hydrazine acetate, to provide the hemiacetal, which was further reacted with DAST to afford the target fluoride donor **10**.

With the two component pieces in hand, we now turned our attention to the completion of the tridecasaccharide synthesis. As outlined in Scheme 4, $\text{BF}_3 \cdot \text{OEt}_2$ -mediated coupling of excess amounts of donor **10** with **2** provided mainly tridecasaccharide **25** (54% yield), along with a small amount of mono-coupled product. The global deprotection of **25** was accomplished in five steps, as shown. Thus, the methyl ester and acetyl groups were removed using excess NaOMe . Next, the phthalimide groups were cleaved, and the resultant free amines were acetylated. We were pleased to find that the 25 benzyl groups and the sulfonamide group could be efficiently cleaved upon exposure to sodium in liquid ammonia.²³ Finally, selective acetylation was accomplished through treatment with acetic anhydride in saturated NaHCO_3 to afford **1**.

Finally, we examined the merger of tridecasaccharide **1** with a peptide domain. Thus, exposure of **1** to Kochetkov conditions²⁴ provided **26** (Scheme 5). Aspartylation of **26** with **27** provided the target glycopeptide **28**, albeit in modest yield.

In summary, we have synthesized homogeneous 2,6-sialylated tridecasaccharide of the Fc sector of IVIG, and successfully coupled the carbohydrate with a peptide domain to provide a glycopeptide adduct (**28**). The merger of **1** with appropriate Fc-derived peptide fragments, and the results of biological evaluations of the glycopeptides, will be reported in due course.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Support was provided by the NIH (CA28824 to SJD). We thank Dr. George Sukenick, Hui Fang, and Sylvi Rusli of SKI's NMR core facility for mass spectral and NMR analysis; Rebecca Wilson for editorial assistance; and Dana Ryan for assistance with the preparation of the manuscript.

References

- (1)(a). Connor SEO, Imperiali B. *Chem. Biol* 1996;3:803. [PubMed: 8939697] (b) Kobata A. *Acc. Chem. Res* 1993;26:319. (b) Feizi T. *Nature* 1985;314:53. [PubMed: 2579340]
- (2)(a). For a review of glycoprotein synthesis, see: Davis BJ. *Chem. Rev* 2002;102:579. [PubMed: 11841255] Though unrelated to our current effort, dramatic advances have been made in the field of enzymatic glycoprotein synthesis: (b) Gamblin DP, Scanlan EM, Davis BJ. *Chem. Rev* 2009;109:131. [PubMed: 19093879] For recent glycoprotein synthetic efforts from our laboratory, see: (c) Kan C, Trzuppek JD, Wu B, Wan Q, Chen G, Tan Z, Yuan Y, Danishefsky SJ. *J. Am. Chem. Soc* 2009;131:5438. [PubMed: 19334679] (d) Yuan Y, Chen J, Wan Q, Tan Z, Chen G, Kan C, Danishefsky SJ. *J. Am. Chem. Soc* 2009;131:5432. (e) Tan Z, Shang S, Halkina T, Yuan Y, Danishefsky SJ. *J. Am. Chem. Soc* 2009;131:5424. [PubMed: 19334683] (f) Nagorny P, Fasching B, Li X, Chen G, Aussedat B, Danishefsky SJ. *J. Am. Chem. Soc* 2009;131:5792. [PubMed: 19341309]

- (3)(a). Anthony RM, Nimmerjahn F, Ashline DJ, Reinhold VN, Paulson JC, Ravetch JV. *Science* 2008;320:373. [PubMed: 18420934] (b) Kaneko V, Nimmerjahn F, Ravetch JV. *Science* 2006;313:670. [PubMed: 16888140]
- (4). Corey, EJ.; Cheung, X-M. *The Logic of Chemical Synthesis*. Wiley-Interscience; New York: 1995.
- (5). Wilson RM, Danishefsky SJ. *J. Org. Chem* 2007;72:4293. [PubMed: 17539594]
- (6)(a). Yamazaki F, Nukada T, Ito Y, Sato S, Ogawa T. *Tetrahedron Lett* 1989;33:4417. (b) Yamazaki F, Sato S, Nukada T, Ito Y, Ogawa T. *Carbohydrate Research* 1990;201:31. [PubMed: 2208190] (c) Paulsen H, Heume M, Nurnberger H. *Carbohydrate Research* 1990;200:127. [PubMed: 2379203] (d) Weiler S, Schmidt RR. *Tetrahedron Lett* 1998;39:2299. (e) Unverzagt C. *Angew. Chem* 1997;109:2078. (f) Eller S, Schubert R, Gundel G, Seifert J, Unverzagt C. *Angew. Chem. Int. Ed* 2007;46:4173. (g) Paulsen H. *Angew. Chem. Int. Ed* 1990;29:823. For syntheses of selected complex bisected glycans, see also: (h) Jonke S, Liu KG, Schmidt RR. *Chem. Eur. J* 2006;12:1274. (i) Matsuo I, Wada M, Manabe S, Yamaguchi Y, Otake K, Kato K, Ito Y. *J. Am. Chem. Soc* 2003;125:3402. [PubMed: 12643681]
- (7). Griffith DA, Danishefsky SJ. *J. Am. Chem. Soc* 1990;112:5811.
- (8).
- (9). Danishefsky SJ, Bilodeau MT. *Angew. Chem. Int. Ed* 1996;35:1380.
- (10). Geeta S, Ole H. *Journal of Carbohydrate Chemistry* 1991;10(5):927.
- (11). Mootoo DR, Konradson P, Udodong U, Fraser-Reid B. *J. Am. Chem. Soc* 1988;110:5583.
- (12). Deng S, Gangadharath U, Chang C. *J. Org. Chem* 2006;71:5179. [PubMed: 16808504]
- (13). Crich D, Sun S. *Tetrahedron* 1998;54:8321.
- (14). Nicolaou KC, Veale CA, Hwang CK, Hutchinson J, Prasad CVC, Ogilvie WW. *Angew. Chem. Int. Ed* 1991;30:299.
- (15). Seeberger PH, Beebe X, Sukenick GD, Pochapsky S, Danishefsky SJ. *Angew. Chem. Int. Ed* 1997;36:491.
- (16). Wu B, Tan Z, Chen G, Chen J, Hua Z, Wan Q, Ranganathan K, Danishefsky SJ. *Tetrahedron Lett* 2006;47:8009.
- (17). Allen JR, Allen JG, Zhang X, Williams LJ, Zatorski A, Ragupathi G, Livingston PO, Danishefsky SJ. *Chem. Eur. J* 2000;6:1366.
- (18). Unverzagt C. *Chem. Eur. J* 2003;9:1369.
- (19). Bhattacharya SK, Danishefsky SJ. *J. Org. Chem* 2000;65:144. [PubMed: 10813908]
- (20). Chen XT, Sames D, Danishefsky SJ. *J. Am. Chem. Soc* 1998;120:7760.
- (21)(a). Shi L, Kim Y-J, Gin DY. *J. Am. Chem. Soc* 2001;123:6939. [PubMed: 11448206] (b) Plante OJ, Palmacci ER, Andrade RB, Seeberger PH. *J. Am. Chem. Soc* 2001;123:9545. [PubMed: 11572674] (19) Hanashima S, Castagner B, Esposito D, Nokami T, Seeberger PH. *Org. Lett* 2000;2:3881. [PubMed: 11101443]
- (22). Hanashima S, Castagner B, Esposito D, Nokami T, Seeberger PH. *Org. Lett* 2007;9:1777. [PubMed: 17411062]
- (23)(a). Iserloh U, Dudkin V, Wang Z, Danishefsky SJ. *Tetrahedron Lett* 2002;43:7027. (b) Wang Z-G, Warren JD, Dukin VY, Zhang X, Iserloh V, Visser M, Eckhardt M, Seeberger PH, Danishefsky SJ. *Tetrahedron* 2006;62:4954.
- (24). Cohen-Anisfeld ST, Lansbury PT. *J. Am. Chem. Soc* 1993;115:10531.

Scheme 1.
Synthetic Strategy Toward Tridecasaccharide 1.

J Am Chem Soc. Author manuscript; available in PMC 2010 November 25.

^aKey: (a) TMSOTf, Toluene/THF, 81%. (b) 1. $\text{PhI}(\text{OAc})_2/\text{BF}_3 \cdot \text{OEt}_2$, CH_2Cl_2 , 2. Py, Ac_2O , 89%. (c) 1. $\text{N}_2\text{H}_4 \cdot \text{AcOH}$, DMF, 2. DAST, CH_2Cl_2 , 82%.

Scheme 3.
Synthesis of Disaccharide Donor **10**.

"Key: (a) $\text{BF}_3 \cdot \text{OEt}_2$, CH_2Cl_2 , 54%. (b) 1. NaOMe/MeOH, THF/MeOH/ H_2O , 2. $\text{H}_2\text{NCH}_2\text{CH}_2\text{NH}_2$, 3. Ac_2O , Et_3N , MeOH, 4. Na, $\text{NH}_3(\text{l})$, 5. Ac_2O , NaHCO_3 , H_2O , 52%. (c) NH_4HCO_3 , H_2O . (d) peptide **27**, HATU, DIEA, DMSO, 20% yield over two steps. **27**: AcHN-Gly-Tyr-Phe-Leu-Val-Asp-Ser-Ser-Gly-Pro-CO₂Me.

Scheme 4.

^a Synthesis of Tridecasaccharide **1** and Glycopeptide **28**